What is IgA nephropathy (igAN)? | FILSPARI® (sparsentan)
WHAT IS IgA NEPHROPATHY (IgAN)? IgAN is a rare kidney disease IgAN is a leading cause of kidney failure. Loss of kidney function is permanent and may result in dialysis or transplant. …
A stronger foundation for kidney preservation | FILSPARI® …
INDICATIONS & USAGE FILSPARI ® (sparsentan) is indicated to slow kidney function decline in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk for disease …
Filspari: Uses, Dosage, Side Effects & Warnings - Drugs.com
Filspari is used for primary immunoglobulin A nephropathy (IgAN), to slow kidney function decline in adults at risk for worsening kidney disease. It is an oral tablet that is taken once a day. …
Filspari for Rare Kidney Disease - HealthCentral
Filspari was approved for reducing proteinuria in people with primary IgAN based on preliminary (or interim) results from the PROTECT trial, which involved 134 medical practices in 18 countries.
Filspari | IgA Nephropathy Foundation
FILSPARI (sparsentan) was approved in February 2023 as a once-daily treatment to lower proteinuria in adults with primary IgA nephropathy. FILSPARI is a prescription medicine to …
FILSPARI® (Sparsentan) - NephCure
Learn more about FILSPARI®, the FDA approved treatment for adults with IgA Nephropathy (IgAN) and how it works to improve kidney function.
Sparsentan: Kidney Disease Uses, Side Effects, Dosage
Sparsentan (Filspari) is a medication used to reduce protein excretion in urine (proteinuria) in adults with primary immunoglobulin A nephropathy (IgAN), a progressive kidney disease. Do …
FILSPARI | FILSPARI® (sparsentan)
FILSPARI® (sparsentan) is for adults with primary igA nephropathy (igAN). See the possibilities with FILSPARI. Please see full Important Safety Information and the Medication Guide, …
Filspari Approved to Slow Kidney Function Decline in IgA Nephropathy
FDA grants full approval to Filspari to slow kidney function decline in adults with primary IgA nephropathy at risk for disease progression.
Mechanism | FILSPARI® (sparsentan)
FILSPARI ® (sparsentan) is indicated to slow kidney function decline in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk for disease progression.